Shingles Vaccine Reduces Cardiovascular Risk by 23% for Up to Eight Years, Study Finds
• A large-scale study of over 1.2 million people found that receiving a shingles vaccine is associated with a 23% lower risk of cardiovascular events, with protection lasting up to eight years.
• The protective effect was strongest in men, individuals under 60, and those with unhealthy lifestyles, with a 26% reduction in major cardiovascular events including stroke, heart attack, and death from heart disease.
• Researchers suggest the vaccine may prevent cardiovascular complications by reducing shingles-related blood vessel damage, inflammation, and clot formation that can contribute to heart disease.
Pfizer-BioNTech COVID-Flu Combo Vaccine Faces Setback Due to Influenza B Response
• Phase 3 trial of Pfizer-BioNTech's combined COVID-19 and influenza mRNA vaccine reveals suboptimal antibody response for influenza B component, necessitating formula adjustments.
• The 8,000-subject study aimed to demonstrate non-inferiority to existing Comirnaty COVID-19 vaccine and standard flu vaccines, following promising phase 1/2 results.
• Setback potentially opens opportunity for Moderna, whose competing COVID-flu combination vaccine showed superior immune responses in Phase 3 trials, targeting potential approval by 2025-2026.
© Copyright 2025. All Rights Reserved by MedPath